A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that
Sponsor: Kumquat Biosciences Inc.
You may qualify if…
- ✓ Histologically confirmed diagnosis of solid tumor malignancy.
- ✓ Unresectable or metastatic disease that has progressed on immunotherapy.
- ✓ No available treatment with curative intent
- ✓ Adequate organ function
- ✓ Measurable disease per RECIST v1.1
You may not qualify if…
- ✕ Active primary central nervous system tumors
- ✕ Cardiac abnormalities
- ✕ History of lung diseases
- ✕ Any condition that may impair drug absorption or prevent oral dosing
- ✕ Known history of immune-mediated colitis and uncontrolled autoimmune diseases
Where it's recruiting
Phoenix
Los Angeles
Denver
New Haven
Jacksonville · Sarasota
Iowa City
Rochester
Cleveland
Austin · Dallas · Houston · San Antonio
Fairfax
Source: ClinicalTrials.gov · NCT06994806 · last updated 2026-03-03